Research ExplorerPublicationsAutologous/reduced-intensity allogeneic stem cell transplant...

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Standard

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. / Gahrton, Gösta; Iacobelli, Simona; Björkstrand, Bo; Hegenbart, Ute; Gruber, Astrid; Greinix, Hildegard; Volin, Liisa; Narni, Franco; Carella, Angelo Michele; Beksac, Meral; Bosi, Alberto; Milone, Giuseppe; Corradini, Paolo; Schönland, Stefan; Friberg, Kristina; van Biezen, Anja; Goldschmidt, Hartmut; de Witte, Theo; Morris, Curly; Niederwieser, Dietger; Garderet, Laurent; Kröger, Nicolaus; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

In: BLOOD, Vol. 121, No. 25, 20.06.2013, p. 5055-63.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gahrton, G, Iacobelli, S, Björkstrand, B, Hegenbart, U, Gruber, A, Greinix, H, Volin, L, Narni, F, Carella, AM, Beksac, M, Bosi, A, Milone, G, Corradini, P, Schönland, S, Friberg, K, van Biezen, A, Goldschmidt, H, de Witte, T, Morris, C, Niederwieser, D, Garderet, L, Kröger, N & EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee 2013, 'Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study', BLOOD, vol. 121, no. 25, pp. 5055-63. https://doi.org/10.1182/blood-2012-11-469452

APA

Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksac, M., Bosi, A., Milone, G., Corradini, P., Schönland, S., Friberg, K., van Biezen, A., Goldschmidt, H., de Witte, T., Morris, C., ... EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee (2013). Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. BLOOD, 121(25), 5055-63. https://doi.org/10.1182/blood-2012-11-469452

Vancouver

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. BLOOD. 2013 Jun 20;121(25):5055-63. https://doi.org/10.1182/blood-2012-11-469452

Bibtex

@article{3f8cc27eb578457d9e67e924d6922021,
title = "Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study",
abstract = "Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.",
keywords = "Aged, Disease-Free Survival, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Time, Transplantation Conditioning, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome",
author = "G{\"o}sta Gahrton and Simona Iacobelli and Bo Bj{\"o}rkstrand and Ute Hegenbart and Astrid Gruber and Hildegard Greinix and Liisa Volin and Franco Narni and Carella, {Angelo Michele} and Meral Beksac and Alberto Bosi and Giuseppe Milone and Paolo Corradini and Stefan Sch{\"o}nland and Kristina Friberg and {van Biezen}, Anja and Hartmut Goldschmidt and {de Witte}, Theo and Curly Morris and Dietger Niederwieser and Laurent Garderet and Nicolaus Kr{\"o}ger and {EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee}",
year = "2013",
month = jun,
day = "20",
doi = "10.1182/blood-2012-11-469452",
language = "English",
volume = "121",
pages = "5055--63",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

RIS

TY - JOUR

T1 - Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

AU - Gahrton, Gösta

AU - Iacobelli, Simona

AU - Björkstrand, Bo

AU - Hegenbart, Ute

AU - Gruber, Astrid

AU - Greinix, Hildegard

AU - Volin, Liisa

AU - Narni, Franco

AU - Carella, Angelo Michele

AU - Beksac, Meral

AU - Bosi, Alberto

AU - Milone, Giuseppe

AU - Corradini, Paolo

AU - Schönland, Stefan

AU - Friberg, Kristina

AU - van Biezen, Anja

AU - Goldschmidt, Hartmut

AU - de Witte, Theo

AU - Morris, Curly

AU - Niederwieser, Dietger

AU - Garderet, Laurent

AU - Kröger, Nicolaus

AU - EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee

PY - 2013/6/20

Y1 - 2013/6/20

N2 - Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.

AB - Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.

KW - Aged

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Time

KW - Transplantation Conditioning

KW - Transplantation, Autologous

KW - Transplantation, Homologous

KW - Treatment Outcome

U2 - 10.1182/blood-2012-11-469452

DO - 10.1182/blood-2012-11-469452

M3 - SCORING: Journal article

C2 - 23482933

VL - 121

SP - 5055

EP - 5063

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 25

ER -